Asbjørn Følling and the discovery of phenylketonuria

Journal of the History of the Neurosciences

Volumn 12, Issue 1, 2003, Pages 44-54

  Christ, Shawn E ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Asbj rn F lling; Genetic disorders; History; Metabolic disorders; Phenylketonuria (PKU); Retardation

Indexed keywords

PHENYLALANINE; PHENYLPYRUVIC ACID;

ACHIEVEMENT; BIOCHEMISTRY; BRAIN DEVELOPMENT; DISEASE SEVERITY; GENETIC DISORDER; HEREDITY; HISTORY OF MEDICINE; HUMAN; INTELLECTUAL IMPAIRMENT; METABOLIC DISORDER; MOTOR DYSFUNCTION; NOMENCLATURE; PHENYLKETONURIA; REVIEW; SKIN DISEASE; URINARY EXCRETION; ART; ARTICLE; FEMALE; HISTORY; MALE; NORWAY; URINE;

FEMALE; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HUMANS; MALE; NORWAY; PHENYLKETONURIAS; PHENYLPYRUVIC ACIDS; PORTRAITS;

EID: 0037872015     PISSN: 0964704X     EISSN: None     Source Type: Journal    
DOI: 10.1076/jhin.12.1.44.13788     Document Type: Review

References (51)

1. Alvord EC, Stevenson LD, Vogel FS, Engle RL (1950): Neuropathological findings in phenylpyruvic oligophrenia (phenylketonuria). Journal of Neuropathology and Experimental Neurology 9: 298-310.
2. Bearn AG (1993): Archibald Garrod and the Individuality of Man. Oxford, Clarendon Press.
3. Bick U, Ullrich K, Stöber U, Möller H, Schuierer G, Ludolph AC, et al. (1993): White matter abnormalities in patients with treated hyperphenylalaninaemia: Magnetic resonance relaxometry and proton spectroscopy findings. European Journal of Pediatrics 152: 1012-1020.
4. Bickel H (1996): The first treatment of phenylketonuria. European Journal of Pediatrics 155: S2-S3.
5. Bickel H, Gerrard AJ, Hickman EM (1953): Influence of phenylalanine intake on phenylketonuria. Lancet 2: 812.
6. Centerwall SA, Centerwall WR (2000): The discovery of Phenylketonuria: The story of a young couple, two retarded children, and a scientist. Pediatrics 105: 89-103.
7. Centerwall WR, Centerwall SA (1961): Phenylketonuria (Følling's disease): The story of its discovery. Journal of History of Medicine and Allied Sciences 16:292-296.
8. Closs K, Følling A (1938): Über das Verhalten der Phenylmilchsäure in vitro und in vivo. Hoppe-Seyler's Zeitschrift Fuer Physiologische Chemie 254:250-255.
9. Closs K, Henriksen SD (1938): Über den Nachweis von d- und 1-Phenylalanin in biologischen Flüssigkeiten. Hoppe-Seyler's Zeitschrift Fuer Physiologische Chemie 254: 107-114.
10. Committee for the Study of Inborn Errors of Metabolism (1975): In Genetic Screening: Programs, Principles, and Research. Washington, DC, National Academy of Sciences.
11. Corsellis JA (1953): The pathological report of a case of phenylpyruvic oligophrenia. Journal of Neurology, Neurosurgery and Psychiatry 16: 139-143.
12. Cowie VA (1951): Phenylpyruvic oligophrenia. Journal of Mental Science 97: 505-531.
13. Dobson J, Williamson M, Azen C, Koch R (1977): Intellectual assessment of 111 four-year-old children with phenylketonuria. Pediatrics 60: 822-827.
14. Følling A (1929): On the mechanism of the ammonium chloride acidosis. Acta Medica Scandinavica LXXI: 221-279.
15. Følling A (1934): Über Ausscheidung von Phenylbrenztraubensäure in den Harn als Stoffwechselanomalie in Verbindung mit Imbezillität. Hoppe-Seyler's Zeitschrift Fuer Physiologische Chemie 227: 169-176.
16. Følling I (1994): The discovery of phenylketonuria. Acta Paediatrica 407: 4-10.
17. Følling A, Closs K (1938): Über das Vorkommen von 1-Phenylalanin in Han und Blut bei Imbecillitas phenylpyrouvica. Hoppe-Seyler's Zeitschrift Fuer Physiologische Chemie 254: 115-116.
18. Følling A, Mohr OL, Ruud L (1945): Oligophrenia phenylpyrouvica. A recessive syndrome in man. Skrifter Det Norske Vitenskapsakademi I Oslo. I. Mat Naturv Klasse 13: 1-44.
19. Følling Elgjo R (1985): Asbjørn Følling: His life and work. In: Berg K, ed., Medical Genetics: Past, Present, Future, Alan R. Liss, Inc., pp. 79-89.
20. Friedman PA, Fisher DB, Kang ES, Kaufman S (1973): Detection of hepatic phenylalanine 4-hydroxylase in classical phenylketonuria. Proc Natl Acad Sci USA 70:552-556.
21. Guthrie R (1996): The introduction of newborn screening for phenylketonuria: A personal history. European Journal of Pediatrics 155: S4-S5.
22. Hommes FA, Moss L (1992): Myelin turnover in hyperphenylalaninaemia: A re-evaluation of the HPH-5 mouse. Journal of Inherited Metabolic Disease 15: 243-251.
23. Jervis GA (1937): Phenypyruvic oligophrenia: Introductory study of fifty cases of mental deficiency associated with excretion of phenylpyruvic acid. Archives of Neurology and Psychiatry 38: 944-963.
24. Jervis GA (1953): Deficiency of phenylalanine oxidizing system. Proceedings of the Society for Experimental Biology and Medicine 82: 514-515.
25. Kaufman S (1963): The structure of the phenylalanine hydroxylation cofactor. Proc Natl Acad Sci USA 50: 1085-1093.
26. Kaufman S (1989): An evaluation of the possible neurotoxicity of metabolites of phenylalanine. Journal of Pediatrics 114: 895-900.
27. Kaufman S, Holtzman NA, Milstien S, Butler IJ, Krumholz A (1975): Phenylketonuria due to a deficiency of dihydropteridine reductase. New England Journal of Medicine 293: 785-790.
28. Koch R, Azen C, Friedman EG, Williamson ML (1984): Paired comparisons between early treated PKU children and their matched sibling controls on intelligence and school achievement test results at eight years of age. Journal of Inherited Metabolic Disease 7: 86-90.
29. Leeming RJ, Blair JA, Rey F (1976): Biopterin derivates in atypical phenylketonuria. Lancet 1: 99.
30. Lidsky AS, Robson KJH, Thirumalachary C, Barker PE, Ruddle FH, Woo SLC (1984): The PKU locus in man is on chromosome 12. American Journal of Human Genetics 36: 527-533.
31. Lou HC, Güttler F, Lykkelund C, Bruhn P, Niederwieser A (1985): Decreased vigilance and neurotransmitter synthesis after discontinuation of dietary treatment for phenylketonuria in adolescents. European Journal of Pediatrics 144: 17-20.
32. Malamud N (1966): Neuropathology of phenylketonuria. Journal of Neuropathology and Experimental Neurology 25: 254-268.
33. Niederwieser A, Curtius H-Ch, Wang M, Leupold D (1982): Atypical phenylketonuria with defective biopterin metabolism. Monotherapy with tetrahydrobiopterin or sepiapterin: Screening and study of biosynthesis in man. European Journal of Pediatrics 138: 110-112.
34. Nowacki PM, Byck S, Prevost L, Scriver CR (1998): PAH Mutation Analysis Consortium Database: 1997. Prototype for relational locus-specific mutation databases. Nucleic Acids Research 26: 220-225.
35. Paine RS (1957): The variability in manifestations of untreated patients with phenylketonuria (phenylpyruvic aciduria). Pediatrics 20: 290-331.
36. Penrose LS, Quastel JH (1937): Metabolic studies in phenylketonuria. Biochemical Journal 31: 266-274.
37. Poser CM, van Bogaert L (1959): Neuropathological observations in phenylketonuria. Brain 82: 1-9.
38. Pueschel SM (1996): Central nervous system effects in individuals with phenylketonuria. Developmental Brain Dysfunction 90: 165-179.
39. Ris MD, Williams SE, Hunt MM, Berry HK, Leslie N (1994): Early-treated phenylketonuria: Adult neuropsychologic outcome. Journal of Pediatrics 124: 388-392.
40. Scriver CR (1995): Whatever happened to PKU? Clinical Biochemistry 28: 137-144.
41. Shedlovsky A, McDonald JD, Smyula D, Dove WF (1993): Mouse models of human phenylketonuria. Genetics 134: 1205-1210.
42. Smith I (1985): The hyperphenylalaninaemias. In: Lloyd JK, Scriver CR, eds., Genetic and Metabolic Disease in Pediatrics, London, Butterworths, pp. 166-210.
43. Smith I, Beasley MG, Ades AE (1990): Intelligence and quality of dietary treatment in phenylketonuria. Archives of Disease in Childhood 65: 472-478.
44. Sydnes S, Følling A (1962): On detection of heterozygotes for phenylpyruvic oligophrenia. Scandinavian Journal of Clinical and Laboratory Investigation 14: 44-46.
45. Tam SY, Roth RH (1997): Mesoprefrontal dopaminergic neurons: can tyrosine availability influence their functions? Biochemical Pharmacology 53: 441-453.
46. Thompson AJ (1995): Phenylketonuria: An unfolding story. In: Robertson MM, Eapen V, eds., Movement and Allied Disorders, Wiley, pp. 83-103.
47. Udenfriend S, Cooper JR (1952): The enzymatic conversion of phenylalanine to tyrosine. Journal of Biological Chemistry 194: 503-517.
48. Ullrich K, Möller H, Weglage J, Schuierer G, Bick U, Ludolph A, et al. (1994): White matter abnormalities in phenylketonuria: Results of magnetic resonance measurements, Acta Paediatrica 407: 78-82.
49. Waisbren SE, Brown MJ, Sonneville LM, Levy HL (1994): Review of neuropsychological functioning in treated phenylketonuria: An information processing approach. Acta Paediatrica 407: 98-103.
50. Welsh MC (1996): A prefrontal dysfunction model of early-treated phenylketonuria. European Journal of Pediatrics 155: S87-S89.
51. Woolf LI (1986): The heterozygote advantage in phenylketonuria. American Journal of Human Genetics 38: 773-774.